Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Tadalafil Mylan, Tadalafil, Erectile Dysfunction, Date of Authorisation: 21/11/2014, Revision: 8, Status: Authorised
Case Medical Research
doi 10.31525/cmr-17cd5cb
Full Text
Open PDF
Abstract
Available in
full text
Date
October 9, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Entecavir Mylan, Entecavir, Hepatitis B, Date of Authorisation: 18/09/2017, Revision: 1, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Instanyl, Fentanyl, Pain,Cancer, Date of Authorisation: 20/07/2009, Revision: 21, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Levetiracetam Sun, Levetiracetam, Epilepsy, Date of Authorisation: 14/12/2011, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Betmiga, Mirabegron, Urinary Bladder, Overactive, Date of Authorisation: 20/12/2012, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Raloxifene Teva, Raloxifene, Osteoporosis, Postmenopausal, Date of Authorisation: 29/04/2010, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Olazax, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 11/12/2009, Revision: 10, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Brimica Genuair, Aclidinium / Formoterol Fumarate Dihydrate, Pulmonary Disease, Chronic Obstructive, Date of Authorisation: 19/11/2014, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Revinty Ellipta, Fluticasone Furoate / Vilanterol, Asthma, Date of Authorisation: 02/05/2014, Revision: 16, Status: Authorised
Case Medical Research
